

January 19, 2021

To,			
BSE Limited	National Stock Exchange of	Mr. Vinod Goel	
General Manager,	India Ltd.	Group CFO and Head Legal &,	
Department of Corporate	The Listing compliance	Company Secretary & Compliance	
Services,	department Exchange Plaza,	Officer,	
14 th Floor, BSE Limited,	Plot no. C/1, G Block,	Panacea Biotec Limited	
PhirozeJeejeebhoy Towers,	Bandra-Kurla Complex	Ambala Chandigarh Highway,	
Dalal Street, Mumbai - 400 001	Bandra (E), Mumbai - 400 051.	Lalru, Punjab 140501	

DISCLOSURE UNDER REGULATION 29(2) OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011

1. Name of the Target Company (TC)		Limited ("Target		
2. Name(s) of the acquirer and Persons Acting in	Vistra ITCL (India) Limited ("Vistra")			
Concert (PAC) with the acquirer	(In our capacity as Debenture Trustee)			
			C-22, G Block,	
		Complex, Bandra (East), Mumbai 400	
	051			
3. Whether the acquirer belongs to Promoter/Promoter group	No			
4. Name(s) of the Stock Exchange(s) where the	BSE Limited (BSE)			
shares of TC are Listed	National Stock Exchange of India Limited (NSE)			
5. Details of the acquisition / disposal as follows	Number	% w.r.t. total	% w.r.t.	
		share/voting	total diluted	
		capital	share/voting	
		wherever	capital of	
		applicable (*)	the TC (**)	
Before the acquisition under consideration,				
holding of:				
a) Shares carrying voting rights				
b) Shares in the nature of encumbrance (pledge/				
lien/non-disposal undertaking/ others)	3,12,62,112	51.04%		
c) Voting rights (VR) otherwise than by shares				
d) Warrants/convertible securities/any other				
instrument that entitles the acquirer to receive shares				
carrying voting rights in the TC (specify holding in				
each category)				
Total (a+b+c+d)	3,12,62,112	51.04%		
Details of acquisition/ Sale	, , ,			
a) Shares carrying voting rights acquired/ sold				
b) VRs acquired/sold otherwise than by shares				
c) Warrants/convertible securities/any other				
instrument that entitles the acquirer to receive shares				
carrying voting rights in the TC (specify holding in				
each category) acquired/sold				
d) Shares encumbered/ invoked/released by the	1,12,29,584	18.33%		
acquirer	, , , -			
Total (a+b+c+d)	1,12,29,584	18.33%		
After the acquisition/ sale holding of:				
a) Shares carrying voting rights				
b) Shares encumbered with the acquirer	4,24,91,696	69.37%		

Registered office:

Tel +91 22 2659 3535 Fax: +912226533297 Email: mumbai@vistra.com www.vistraitcl.com Page 1 of 2



c) VRs otherwise than by shares			
d)Warrants/convertible securities/any other			
instrument that entitles the acquirer to receive shares			
carrying voting rights in the TC (specify holding in			
each category) after acquisition			
Total (a+b+c+d)	4,24,91,696	69.37%	
Mode of acquisition/ sale (e.g. open market /off	Pledge of equity shares		
market/ public issue / rights issue / preferential			
allotment / inter-se transfer, etc.)			
Date of acquisition / sale of shares/VR or date of	Pledge date: January 15, 2021		
receipt of intimation of allotment of shares,			
whichever is applicable			
Equity share capital / total voting capital of the TC	6,12,50,746 equity shares		
before the said acquisition/ sale	(As per the Shareholding pattern available on BSE		
	website for the quarter ended December 2020)		
Equity share capital/ total voting capital of the TC	6,12,50,746 equity shares		
after the said acquisition/ sale	(As per the Shareholding pattern available on BSE		
1	website for the quarter December 2020)		
Total diluted share/voting capital of the TC after the		*	,
said acquisition			
			1 0

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Note:

1,12,29,584 equity shares of the Company have been pledged with Vistra in the capacity as Debenture Trustee to secure Non-convertible Debentures issued by Target Company's wholly owned subsidiary, Panacea Biotec Pharma Limited.

The primary onus of complying with the provisions of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 is of the lender, debenture holder and not on the Trustee. However, out of abundant caution, Vistra in its capacity as security trustee and debenture trustee is disclosing and filing this disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

For Vistra ITCL (India) Limited

reven

Authorized Signatory

Place: Mumbai

Registered office:

The IL&FS Financial Centre, Plot C- 22, G Block, 7th Floor Bandra Kurla Complex, Bandra (East), Mumbai 400051 Tel +91 22 2659 3535 Fax: +912226533297 Email: mumbai@vistra.com www.vistraitcl.com Page 2 of 2

Vistra ITCL (India) Limited